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In this retrospective review, metabolic factors present in diabetic patients who underwent 
bariatric surgery were compared against those who were treated with medical therapy alone. 
These factors include: diabetes remission, glycosylated hemoglobin levels, medication use, 
changes in beta cells function, insulin sensitivity, incretin levels, weight loss, lipid profiles and 
blood pressures. Following bariatric surgery, patients observed superior changes in diabetes 
remission rates, glycosylated hemoglobin levels, medication use, beta cell function, insulin 
sensitivity, incretin levels, and weight loss when compared to those who were treated with 
medical therapy alone. Blood pressure changes were not significantly different among the two 
treatment groups. Between 3-5 years after surgery, the surgical group showed significantly lower 
levels of low-density lipoproteins, total cholesterol, and triglycerides. In addition, high density 
lipoprotein values were raised in greater amounts following bariatric surgery. Diabetic patients 
who undergo bariatric surgery report higher amounts of minor complications following surgery 
than those who are not diagnosed with diabetes. This paper also examined the side effects and 
safety of bariatric surgery to determine associated risks and benefits. Nutritional deficiencies, 
bone metabolism, dumping syndrome, and surgical complications should be considered potential 
risk factors by patients who are considering bariatric surgery to treat their diabetes.  Benefits 






         The prevalence of diabetes has nearly doubled between 1980 and 2014 worldwide.1 
Increases in diabetic populations are seen in low to middle income countries and in men more so 
than women.1 This chronic and highly prevalent disease was estimated to be affecting 415 
million people globally in 2015 and is predicted to rise to 642 million by 2040.2 Type 2 diabetes 
is by far the most common type of diabetes (>90%)3 and is defined as elevated blood glucose due 
to progressive insulin resistance leading to decreased beta cell function. 
         It is a common belief among researchers that a sedentary lifestyle and Western style diet1 
are among the most prevalent risk factors for developing type 2 diabetes. These two factors are 
also associated with increased risk of developing obesity which is commonly noted as a 
complication for type 2 diabetic patients.1 Other literature suggests environmental factors, gut 
microbiome, and genetics as possible risk factors of developing type 2 diabetes as well.The list 
of sequelae from diabetes is long and often complicated by other comorbid risks. Diabetes is 
often associated with an increased mortality rate greater among women than men when 
compared to those without diabetes.4 If you examine patients who are diagnosed with diabetes 
and morbid obesity (BMI > 35 with comorbidities, or BMI >40 without comorbidities) then 
mortality rates show a two-fold excess when compared to lean subjects.4 
         Current diabetes treatment recommendations modeled by the American Association of 
Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) have a 
comprehensive and multifaceted approach including lifestyle changes focused on diet, physical 
activity, sleep, and smoking cessation.5 However this approach seems to be less effective and has 
pushed the hand of providers to their prescription pads.5  There are several medications used to 
treat diabetes but these medications do not come without their own side effects, risks, and 
complications. Up to 90% of patients with type 2 diabetes do not reach treatment goals designed 
to reduce significant complications.6 These grim results again lead researchers and providers to 
come up with new solutions which is when bariatric surgery s effects on diabetes became a topic 
of interest.  Currently, based on National Institutes of Health (NIH) guidelines which were last 
revised in 1991, only patients with type 2 diabetes and a body mass index (BMI) of  35 kg/m2 or 
more are eligible for bariatric surgery.7 Since the NIH recommendations were published a 
plethora of new evidence has been generated providing peer reviewed data suggesting that 
bariatric surgery has a powerful effect on type 2 diabetes. The data suggests that bariatric 
procedures' positive effect on the health of diabetic patients stems from reduced food intake and 
healthier body weight as well as weight-independent mechanisms.8 There are several types of 
bariatric surgery used in the treatment of diabetes but this article will focus on biliopancreatic 
diversion, Roux-en-Y gastric bypass, laparoscopic adjustable gastric band, and sleeve 
gastrectomy. 
This review article will examine how intensive medical management compares to 
bariatric surgery modalities in the treatment of diabetes paying special attention to their efficacy 
in glycemic controls and effects on related comorbid disease risk factors.  In addition, this article 
will examine the safety and adverse effects of bariatric surgery that are currently keeping some 
from exploring it as a treatment option. 
Methods: 
Using PubMed, Google Scholar, and UpToDate a thorough examination of literature was 
done to explore the comparison of intensive medical therapy to bariatric surgery in patients with 
type 2 diabetes. In addition to the comparison between the treatment options the same search 
engines were utilized to identify articles that included safety, side effects, and complications of 
bariatric surgery modalities. The keywords used in this search include “prevalence of diabetes , 
“risk factors for developing diabetes , “diabetes signs and symptoms , “bariatric surgery and 
diabetes , “bariatric surgery versus medication in treatment of diabetes , “bariatric surgery 
complications , “bariatric surgery and 10 year , “bariatric surgery and safety.  Reference lists 
were also examined for associated and relevant articles. 10 articles were identified and utilized as 
references for comparison between medical management and bariatric surgery while 6 articles 
were analyzed that addressed the safety, side effects, and complications of bariatric surgery. In 
addition, 8 articles were examined for specifics of diabetes, bariatric surgery, and background 
information. Search options included peer reviewed articles that consisted of randomized control 
trials, clinical trials, observational studies, meta analyses, and review articles. Each study 
included recent data (within 10 years) except for 1 long term retrospective cohort study from 
2007 which gathered mortality rates of bariatric surgery.22 An expert interview was conducted 
with Dr Michael McRae on 5/22/2020 via phone and was followed up through emailed prompt 
(appendix A). Major inclusion criteria were peer reviewed articles focusing on medical 
interventions compared to bariatric surgeries in type 2 diabetic patients, articles that examined 
mortality rates and complications of bariatric surgery, and articles that provided information on 
how bariatric surgery relates to diabetes control. Exclusion criteria removed articles that included 
participants less than 18 years old, pregnant women with gestational diabetes, or included 
surgery modalities other than biliopancreatic diversion, Roux-en-Y bypass, adjustable gastric 
band, and sleeve gastrectomy. All the articles and data utilized in this review were analyzed and 
assessed by the author of this review. Relevant statistically significant findings and information 
were extracted and investigated. The quality of each study was evaluated by the type of design, 
relevant information, selection biases, and how their conclusions compare to current literature.  
Background: Literature Review 
         Diabetes mellitus (DM) is a metabolic disorder in which patients suffer from high blood 
sugar levels because their bodies do not respond to, or just simply lack, insulin.9 Insulin is a 
hormone secreted by the beta cells within the pancreas that signals the body to uptake glucose 
into the cells in response to increased blood glucose levels. In addition, this hormone inhibits 
hepatic glucose production which lowers blood glucose levels.9 Type 2 diabetes can be defined 
as an over stimulation of receptor cells from constant elevated blood glucose levels. Eventually 
this leads the body to have a decreased sensitivity to the insulin being secreted.9 This review will 
only focus on patients with type 2 diabetes and how bariatric surgery affects glycemic control 
and outcomes. In the chronic setting diabetes can lead to renal failure, blindness, diabetic foot 
disorders, neuropathies, and cardiovascular diseases.9 Despite significant effort from the medical 
community, diabetes has remained the 5th leading cause of death worldwide.9 Diabetic patients 
have a reported 15% increased risk of premature death and their life expectancy is decreased by 
20 years when compared to those without the disease.9  
         The American Diabetes Association (ADA) recommends that screening for diabetes 
begins for all people at age 45 and is repeated every three years. Screening tests include: fasting 
plasma glucose test (FPG), random glucose test , glycosylated hemoglobin level (HbA1c), and an 
oral glucose tolerance test (OGTT).10  
         Due to the complexity of diabetes, medical professionals implore multifaceted treatment 
plans consisting of lifestyle modifications, medications, and bariatric surgery as a common last 
resort. Intensive medical therapy to treat diabetes may be defined as a combination of lifestyle 
changes and medications that align with the goals and standards within current literature. 
Medications are often prescribed based on glycemic control, lipid control, patient tolerability, 
and efficacy. The most common medication classes used in the treatment of diabetes are 
Biguanides, Sulfonylureas, Thiazolidinediones, Alpha Glucosidase inhibitors, DPP4 inhibitors, 
Amylin Mimetics, and Insulin. Due to the individual nature of diabetes treatment plans specific 
medications utilized for glycemic, blood pressure, or lipid control will not be identified nor were 
they individually tracked among the studies. 
         Bariatric surgery is a horizon term and can be used to describe several surgical 
procedures including laparoscopic adjustable banding (ABG), Roux-en-Y gastric bypass 
(RYGB), sleeve gastrectomy (GS), and biliopancreatic diversion (BPD). Laparoscopic adjustable 
banding is defined as an adjustable silicone band being placed around the superior portion of the 
stomach, creating a small gastric pouch.11 The diameter of the band can be changed by a provider 
as needed.11 Roux-en-Y-gastric bypass is a surgical procedure where a small, vertically oriented 
pouch is made from the superior portion of the stomach.11 This pouch remains connected to the 
esophagus at one end and, at the other end is attached to a section of the small intestine, thus 
bypassing the remaining gastric contents and the duodenum.11 Sleeve Gastrectomy involves a 
surgical diversion of the stomach which is done vertically, reducing the size by about 75%.11 
This procedure is not reversable.11  Lastly the Biliopancreatic Diversion consist of first 
performing a distal horizontal gastrectomy.11 This alimentary limb is then anastomosed to the 
distal small intestine.11 The bypassed small intestine carrying bile and pancreatic sections is 
known as the biliopancreatic limb and is connected to the small bowel proximal to the ileocecal 
valve. 11 This small proximal portion is the only limb segment where digestive secretions and 
nutrients mix thus this procedure can cause marked malabsorption.11 According to recent 
surveying, RYGB and SG account for a large majority of the bariatric procedures currently being 
done 45% and 37%, respectively, 11 whereas the use of AGB has fallen to around 10% and BPD 
rates are less than 2%.11 
The mechanism by which many of these surgical modalities treat diabetes has been a 
topic of recent research. It is reported that bariatric surgery induces weight loss which improves 
insulin sensitivity among cells, decreases hyperinsulinemia, and improves beta cell function by 
weight independent factors related to an incretin effect.12 After bariatric surgery, levels and 
activities of proteins which are regulated by insulin, increase. The exact reason behind this 
observation is not known but it likely correlated to a change in diet and decreased fat percentage 
which is seen in greater abundance following bariatric surgery.12 Due to an increased insulin 
sensitivity following bariatric surgery, one study noted significantly increased levels of incretins 
over the medical therapy group.12 Incretins are released in response to a patient eating and will 
also increase with the secretion of insulin. Incretins are peptides that act by assisting in insulin 
secretion and by decreasing glucagon secretion. This is extremely beneficial to patients trying to 
control their glycemic levels as glucagon breaks down lipids in the liver to create glucose which 
is secreted into the blood. These changes significantly improve glycemic control in patients, 
decrease antidiabetic medication use, and hopefully provide diabetes remission. Dr Michael 
McRae (appendix A), was asked for his thoughts on how bariatric surgery works in treating type 
2 diabetes. His response was “The complete mechanism behind how bariatric surgery improves 
outcomes in type 2 diabetes is unclear. Many patients will begin having significant drops in their 
blood sugar and insulin requirements immediately following surgery before any weight loss 
occurs. The improvement in lipid profiles, blood pressures and blood sugars secondary to weight 
loss can be explained by the improvement in insulin resistance. When fat is removed from tissues 
such as the liver, muscles, ect. the insulin receptor begins working much better. This allows the 
endogenous insulin produced by the pancreas to start working much better and subsequently 
improve blood sugar, lipid profiles, and blood pressures.  
Currently bariatric surgery is only recommended for diabetic patients if they have a body 
mass index (BMI) greater than 35 kg/m2.7 This recommendation is based on the National 
Institutes of Health Guidelines which was endorsed by the centers for Medicare and Medicaid.7 
Patients with a BMI less than 35 kg/m2 are simply offered medications and lifestyle treatment 
options.7 Millions of patients with type 2 diabetes have a BMI <35; for many of them, metabolic 
surgery due to the NIH guidelines is not an option because of the financial burden of being 
forced to pay out of pocket for the procedure.7 Without substantial evidence, the NIH is unlikely 
to change the bariatric surgery guidelines for patients with diabetes. 
Bariatric Surgery VS Intensive Medical Management (Lifestyle 
Changes/Medications) 
Diabetes remission 
         Multiple studies have shown a remission of diabetes through bariatric surgery.7,13-15 There 
is an increasing number of studies that provide evidence that bariatric surgery shows a superior 
efficacy when compared to non-surgical treatment options in causing remission in diabetic 
patients. 7,13-15  In general, remission of diabetes is determine by a glycosylated hemoglobin 
(HbA1c) level of <6.5%, and a fasting plasma glucose (FPG) less than 126 mg/dl.14 However 
each of the following studies provide different definitions of remission which will be reviewed.  
Mingrone et al., defined remission as FPG <100mg/dl and a HbA1c <6.5% without the 
use of diabetic medication. The study participants were divided into 3 groups, medical therapy 
only n=20, RYGB n=20, and BPD n=20. The medical therapy group received individualized 
treatment recommendations based upon the individual s needs and current ADA guidelines. 
After two years, remission has occurred in 0% of the patients who were receiving medical 
therapy alone, 75% who received RYGB, and 95% of patients who had undergone a BPD.15 
 Parikh et al., defined remission as no longer meeting the ADA criteria for type 2 diabetes 
without the use of diabetic medication. This study included 48 participants n=20 in the surgical 
group who could choose from RYGB, GS, or AGB as treatment options, and n=24 in the medical 
therapy alone group. Subjects in the medical therapy group were educated and encouraged to 
participate in group or individual sessions focusing on nutrition, physical activity, and goal 
setting. In addition, these sessions reviewed at home glucose data and made adjustments to their 
diabetic medications as needed. Patients were examined at 6 months and it was found that 
diabetes remission had occurred in 65% of patients in the surgical group while 0% of patients in 
the medical therapy group had achieved remission (p<0.0001).7 
Cummings et al., defined remission of diabetes as HbA1c <6.0% while being off all 
diabetes medication. There were n= 15 patients in the surgical group who received a RYGB and 
n=17 in the medical therapy group. Patients in the medical therapy group were instructed in diet 
training weekly for the full year of the study. They also participated in 3 supervised exercise 
sessions and were encouraged to work out >2 times per week at home for the first 6 months. The 
following 6 months they participated in 1 supervised workout and were encouraged to exercise 
>4 days per week at home. Both groups received medical care including medication for their 
diabetes through their own family practitioner based upon the ADA guidelines. This study found 
that after 1 year 60% of patients who received the RYGB versus only 5.9% who received 
medical therapy alone had achieved remission (p=0.002).13 
In a similar study comparing RYGB to non-surgical treatment and examining remission 
of type 2 diabetes Simonson et al., followed patients for an additional 2 years. This study defined 
remission as having a HbA1c <6.5% and a FPG<126mg/dl. The study included 19 patients who 
underwent RYGB and 19 patients who received intensive lifestyle management with 
medications. The non-surgical group participated in two hour group sessions conducted weekly 
during a 12-week induction phase. These sessions included supervised group exercise, 
adjustments to medication, and didactic work. The participants were encouraged to limit calorie 
intake to 1500-1800 kcal, exercise for 300 minutes per week, and were given diabetes 
medications that are not associated with weight gain or hypoglycemia. During this trial, all 
participants were receiving antidiabetic medications. After 3 years it was found that 42% of the 
RYGB group had achieved remission of diabetes. 7 out of the 8 who achieved remission were 
taking no antidiabetic medications. While no patients who were in the non- surgical group 
achieved a remission. When comparing it is obvious that the RYGB group showed significant 
improvement in remission of diabetes to the non-surgical group at 3 years (p=0.005).14 In 
summary these studies provide consistent evidence that remission can be achieved more 
frequently in bariatric surgery populations than medical therapy alone, the duration of 
effectiveness remains in question. 
Glycosylated Hemoglobin A1c levels 
Glycosylated hemoglobin values are used by providers to determine the average blood 
glucose levels in patients for the past 2-3 months. It is often also used as an indicator of how well 
a patient s diabetes is controlled. This review identified many studies which demonstrate that 
bariatric surgery is superior to non-surgical medical therapy in reducing HbA1c levels.6,7,12-19 
The different surgical modalities used include RYGB 6,7,12-19, GS7,12,16-18, AGB7, and BPD15. In a 
prospective randomized control trial Schauer et al., examined 150 patients who underwent either 
intensive medical therapy (lifestyle changes plus medications n=50), sleeve gastrectomy (SG) 
plus medication n=50, or route- en-Y- gastric bypass (RYGB) plus medication n=50. The 
participants average BMI was 37 +/- 3.5, their mean A1C was 9.2 +/-1.5% suggesting 
uncontrolled diabetes, and their mean duration of diabetes was 8.4 +/- 5.2 years. These patients 
were examined for changes at 1 year16, 3 years17, and 5 years18. The primary endpoint for these 
trials was to evaluate the number of patients who could achieve a targeted HbA1c of 6% or less. 
Schauer (2012) et al.,  recorded that 5 of 41 (12%) in the medical therapy group, 21 of 50 (42%) 
in the RYGB group, and 18 of 49 (37%) of the SG group were able to achieve a HbA1c value 
less than or equal to 6%. This study show significant improvement in reaching HbA1c goals in 
the surgical groups when compared to the medical therapy group (p<0.008).16 However there 
was no significant difference when comparing the two surgical groups (p=0.59).16 Schauer 
(2014) et al., recorded a decreased in the number of patients achieving the endpoint of the studies 
at 3 year follow up. Showing that 5% of patients in the medical therapy group, 38% of patients in 
the RYGB group, and 24% of patients in the GS group sustained HbA1c levels at or below 6%. 
Still the surgical groups provided significant improvement when compared to medical therapy 
(p=0.01).17 Additionally, this study showed that patients in the two surgical groups had a 
significant absolute decrease of 2.5 percentage points in HbA1c levels sustained at 3 years while 
the medical therapy group showed a reduction of 0.6 percentage points.17 Schauer (2017) et al., 
showed that after 5 years 29% of patients who received gastric bypass, 23% of patients who 
received a sleeve gastrectomy, and 5% of patients who received intensive medical therapy alone 
were able to reach an HbA1c level of 6% or lower. Showing that SG and RYGB significantly 
improved sustained HbA1c levels superior to that of medical therapy alone at 5 years (p<0.03).18 
Although most research indicates that bariatric surgery lowers HbA1c levels more 
effectively than medical therapy alone, one article found no significant difference between the 
methods for helping patients achieve HbA1c levels <6%.14 In a prospective randomized trial 
Simonson et al., compared 38 patients (n=19 in RYGB group and n=19 in nonsurgical group) 
whose mean BMI was 36 +/- 3.4, HbA1c was 8.5 +/- 1.3% and their duration of diabetes was 
10.6 +/- 6.6 years. Participants in the non-surgical group received intensive medication and 
weight management therapy. While the surgical group received medication therapy and RYGB 
surgery. After 3 years there were no significant differences between the surgical group and non-
surgical group in the number of patients who achieved a HbA1c <6% (p=0.104)14, which differs 
from Schauer (2014)17 findings at 3 years. 
Only one study provided a significant difference in HbA1c levels when comparing the 
different surgical modalities used to treat diabetes. Mingrone et al., found at 2 year follow up the 
average percent change in HbA1c levels from a baseline of 8.65% had decreased by 0.72% in the 
medical therapy group, 2.16%  in the RYGB group, and 3.71% in the BPD group. The two 
surgical groups significantly improved HbA1c when compared to the non-surgical group 
(p=0.003, p<0.001) respectively. However, it was also found that the BPD group significantly 
outperformed the RYGB group (P=0.001) in decreasing HbA1c levels .15 Therefore some 
providers may want to consider BPD in patients that remain at significant risk due to a lack of 
blood glucose control. However, surgical risks and side effects between the two surgeries should 
be weighed when making the decision. 
Antidiabetic Medication Use 
         It is important to distinguish the difference of medication use between bariatric surgery 
and medical therapy groups. By doing so providers can validate their suspected hypothesis that 
bariatric surgery allows for better blood glucose control while eliminating medication use as a 
potential risk for biases in the results between both treatment options. This review article 
identified many studies which showed a significant and superior decrease in glycemic 
medication use following bariatric surgery when compared to medical therapy alone.6,12-14,16,19 In 
addition to less glycemic medication use, 4 studies examined total medication use and found 
significant decreases in hypertension and hyperlipidemia medications following bariatric surgery 
versus medical therapy.13,14,16,19 This review will remain focused on the findings for glycemic 
medication use. 
In a prospective randomized control trial Schauer (2012) et al, examined 150 patients and 
found that after 1 year, the percentage of patients using insulin in the medical therapy did not 
have a significant change, though it did decrease from 51% of patients to 38%. While insulin use 
in the RYGB group had decreased from 46% of patients at baseline to 4%. Similar results were 
found in the SG group who showed 45% of patients using insulin at baseline decreased to 8% at 
one year. When comparing the two surgical groups to medical therapy the significant decrease in 
insulin use was apparent (p<0.001 for both comparisons).16 In that same cohort of patients 
Schauer (2017) et al., found similar results at their 5 year follow up showing that approximately 
89% of patients in the two surgical groups were not using insulin for glycemic control and 
patients were still able to maintain an average HbA1c of 7%. Whereas 61% of patients in the 
medical therapy group were not taking insulin at 5 years with an average HbA1c of 8.5%, 
suggesting uncontrolled diabetes and the need for increased treatment.18 
In another study examining medication use between bariatric surgery and medical 
therapy groups Serrot et al., at the University of Minnesota, performed a retrospective review on 
34 patients (n=17 in RYGB, and n=17 in non-surgical group). Participants in the RYGB surgical 
group were treated with medications, dietary education, and lifestyle counseling. The non-
surgical group participants were treated with medications focused on controlling hyperglycemia, 
and with counseling regarding nutrition, exercise, and weight management. The RYGB and non-
surgical groups had comparable medication use at baseline. After 1 year, the RYGB group was 
taking significantly less medication for glycemic control, with 71% of patients taking fewer 
medications compared to 6% in the non-surgical group (p<0.001). Important to note though was 
that 3 of the 9 patients in the surgical group who choose not to take glycemic medications had a 
HbA1c >7% which suggests the need to return to medication therapy.19 
Changes in insulin sensitivity/Pancreatic Beta cell function/Incretins   
         As aforementioned the exact mechanism by which bariatric surgery improves insulin 
sensitivity, pancreatic beta cell function, or incretin release is unknown. Regardless of the 
mechanism, an improved beta cell function, incretin release, and increased insulin sensitivity is a 
welcomed outcome for any patient seeking treatment for type 2 diabetes. This review identified 
two studies which provide data showing that bariatric surgery significantly improved insulin 
sensitivity 7,12, beta cell function12, and increased incretins12 when compared to medical therapy 
alone.7.12 The first study conducted by Parikh et al., examined 44 patients (n=20 in surgical 
group, n=24 in medical therapy group) through a prospective randomized control trial. Patients 
in the surgical group were able to choose from RYGB, SG, or AGB as surgical modalities while 
the medical therapy group utilized intensive lifestyle interventions focused on diet, physical 
activity, and counselling. Both groups received medication treatment for their diabetes according 
to current guidelines. Parikh et al., unutilized a formula called The Homeostatic Model of Insulin 
Resistance (HOMA-IR); to assess changes in insulin resistance between the two groups at 6 
months follow up. It was noted that the surgery group had decreased HOMA-IR by 4.6 while the 
medical therapy group saw an increase in insulin resistance of 1.6 (p=0.0004). When performing 
a 75g oral glucose test, patients who had surgery recorded an average blood glucose of 130 
mg/dl compared to the medical therapy group who averaged 306 mg/dl after 2 hours (p< 
0.0001).7 
         In the second study, Kashyap et al. conducted a randomized control trial on 54 patients 
(n=17 intensive medical therapy group, n=18 in RYGB group, and n=19 in SG group). Changes 
in insulin sensitivity, beta cell function, and incretin release between the surgical and medical 
groups were examined. The medical therapy group treatment followed ADA guidelines and used 
the latest U.S. Food and Drug Administration approved medications to treat their diabetes. 
Patients who were treated with surgery also received diabetes medications in line with ADA 
guidelines. Utilizing the (matsuda index) in non insulin- using patients, this study recorded that 
median values for  insulin sensitivity increased at 24 months in the RYGB group (n=9) by 2.7 
fold when compared to medical therapy alone (p<0.001). The SG group (n=10) recorded a 1.2-
fold increase and there was no change recorded in the medical therapy group alone. This study 
also examined changes in median values for pancreatic beta cell function using an oral 
disposition index at 24 months. The patients who received RYGB saw a 5.8 fold increase in 
median beta cell values when compared to medical therapy alone while there was no significant 
increase from the GS group. Through a sub study cohort correlation these researchers found that 
the beta cell changes were significantly related to the change in percentage of truncal fat 
(P=0.0013) and body weight (p<0.001). Lastly this study examined median levels of Glucagon-
like- peptide-1 (GLP-1) changes between the surgical and medical therapy group at 24 months. 
Taking into account fasting, this study found GLP-1 median levels 60 minutes after mixed-meal 
injection (8 oz of Boost drink) increase drastically after RYGB (12.5 vs 2 pmol/L; p<0.001), SG 
(7.3 vs 2.4 pmol/L; p<0.01, and did not change with the medical therapy group (1.5 vs 1.4 
pmol/L; p=not significant). Suggesting that bariatric surgery effectively increases incretin release 
up to two years following surgery when compared to medical therapy alone.12  
Comorbid Risk factors 
         In addition to improving blood glucose, bariatric surgery can provide changes in weight, 
BMI, blood pressure, and lipid levels which have all been indicated as risk factors for significant 
sequelae in diabetic patients. Many studies provide data suggesting that bariatric surgery is 
superior to medical therapy alone in providing and sustaining a decrease in weight or BMI.6,7,12-19 
Weight loss difference between bariatric surgery and medical therapy are often seen greatest at 1 
year follow up14 and though the difference in weight loss between the groups narrows, bariatric 
surgery is still superior at 5 years.18 The greatest difference in weight and BMI changes are 
found with patients who have undergone BPD due to the malabsorption effect of this surgery.15 
         Conflicting evidence exists among studies that examined blood pressure changes in 
bariatric surgery groups versus medical therapy. With emerging evidence the ADA 
recommendations have become more relaxed in recent years and are now recommending a 
systolic blood pressure (SBP) goal of <130 for patients with type 2 diabetes.6 Two studies 
reported a significant decrease of SBP in the surgical groups when compared to medical 
therapy.6,13 Both of these studies examined RYGB and followed up with patients at 1 year. 
However, these results were not shared among 3 other studies who used the same treatment 
modality and followed patients at 1 to 5 years.7,18,19 These findings suggest that bariatric surgery 
should not be used solely for the indication of controlling hypertension among diabetic patients. 
         Many studies utilized lipid panel values to assess for changes among surgical groups and 
those who were given medical therapy.6,7,12-16,19 One study that examined changes at 6 months 
between the two groups found no significant changes in lipid levels however patients in this 
study also had baseline levels that were normalized before treatment.7 There were 3 studies that 
compared RYGB to medical therapy with a 1 year follow up and only one found an increase in 
high density lipoproteins13 while there were no significant differences noted in low density 
lipoproteins, total cholesterol, or triglycerieds.6,13,19 Two studies examined difference in lipids at 
2 years.12,15 Interestingly HDL significantly increased with RYGB in one study15 but did not 
change significantly with the second study.12 In evaluations of longer follow up times 3 studies 
examined outcomes of RYGB and SG at 3 years14,17 and 5 years.18 These articles provided data 
that was different from early studies showing a significant decrease in in LDL14, total 
cholesterol14, triglyceries14,17,18, and a significant increase in HDL.14,17,18 This evidence suggest 
the need to wait 3-5 years before evidence of bariatric surgery shows superior benefit compared 
to medical therapy in lipid levels. 
Safety and Side Effects of Bariatric surgery 
         Common questions found among patients who have developed uncontrolled diabetes and 
meet criteria for bariatric surgery center around its safety and correlated side effects. This review 
includes 2 studies which analyzed 30-day outcomes in patients who had bariatric surgery.20,21 
The first study conducted by Birkmeyer et al., examined rates of complications in 15,275 
patients who had undergone bariatric surgery(n=5380 in AGB group, n= 864 in SG group, and 
n=9041 in RYGB group). Fatal complications occurred in 2 patients who had received an AGB 
(0.04% risk), 0 patients who received SG, and 13 patients who received RYGB (0.14% risk.) 
Potentially life-threatening complications, defined as venous thromboembolism, cardiac, renal, 
or respiratory failure, occurred in 1.5% of patients overall. This percentage varied from 0.58% in 
patients with AGB surgery to 2.1% in patients who received gastric bypass.20 
Similarly in a longitudinal assessment of bariatric surgery at 10 clinical sites in the 
United States 4610 patients (n=3412 in RYGB, n= 1198 AGB) were evaluated for major adverse 
outcomes.21 Major adverse outcomes included death, deep vein thrombosis, reintervention, or 
failure to be discharged within 30 days and were seen in 4.1% of patients: 1% of patients who 
received AGB, 4.8% who received laparoscopic RYGB, and 7.8% of those who underwent open 
RYGB. When evaluated independently it was noted that 0.3% of patients had died: none of the 
1198 who underwent AGB, 0.2% of 2975 who underwent laparoscopic RYGB, and 2.1% of 437 
who had undergone an open RYGB. Also, deep vein thrombosis occurred at a rate of (0.4%): 3 
in the AGB group (0.3%), 6 in the laparoscopic RYGB group (0.2%), and 9 in the open RYGB 
(2.1%).21 These studies provided evidence that major complications do occur from bariatric 
surgery. However, the relative rates in which they occur are extremely low which suggests that 
bariatric surgery should be considered a safe procedure. 
         When considering the short term risks compared to the long term benefits of bariatric 
surgery, Adams et al. in a retrospective cohort study examined 15850 individuals (n=7925 in 
RYGB group, n=7925 in nonsurgical) who were matched for age, sex, and self-reported BMI. 
Subjects were studied for causes of mortality at an average of 7.1 years following surgery. 
Analyzing the specific cause of mortality this study showed that the RYGB group observed a 
decrease in mortality rates by 56% in coronary artery disease, 92% for diabetes related deaths, 
and 61% for cancer when compared to those who did not have bariatric surgery. These results 
were all examined beyond 5 years from baseline which provides evidence that could be reviewed 
with patients who are considering bariatric surgery as a treatment option to help control their 
diabetes.22 
         Studies which review the safety of bariatric surgery specifically in patients with type 2 
diabetes are extremely limited. This review could only identify 1 article that provided data on SG 
safety outcomes in type 2 diabetic patients.23 In a retrospective cohort study Guetta et al., 
examined 984 patients (n= 841 without type 2 diabetes diagnosis, n=143 with type 2 diabetes) 
for severe and mild complications. Subjects were examined at 1 week, 4 months, 8 months, and 
12 months. Early complications were considered <60days post-surgery and late complications 
are defined as > 60days post-surgery. Severe complications were defined as (requiring 
intervention under general anesthesia, placement in an intensive critical care unit, multiorgan 
failure, or death). While mild complications were defined as (any deviation from normal 
postoperative course, requiring any drug therapy, parenteral nutrient, blood transfusion or 
intervention not under general anesthesia.) At 1 year this study only recorded 1 death found in 
the non-type 2 diabetes group, the cause of death was not reported. When comparing the two 
groups through a multivariate binomial logistic regression, type 2 diabetes proved to be the only 
significant variable of difference. This study noted a significant higher percentage of mild 
complications seen in patients who had been diagnosed with diabetes compared to those who 
were not (8.4% versus 3.8%, p=0.01) respectively. However, there was no difference in severe 
complications at 1 year (p=0.615).23 
In addition to examining significant and severe complications of bariatric surgery this 
review utilized 2 studies which examine nutritional deficiencies and other more common side 
effects of bariatric surgery.11,24 Lupoli et al., reports anemia as one of the most common side 
effects seen in bariatric surgery with a prevalence between 33-49% at 2 year follow up.11 Tack et 
al., reports dumping syndrome as another prevalent sequelae identifying prevalence of up to 40% 
in individuals who were treated with RYGB or SG.24 Vitamin deficiencies also remain high 
among patients who have undergone bariatric surgery.11,24 Most common among these deficiency 
are B12(up to 62%) , folate (up to 39%), and iron (up to 44%).11,24 Vitamin deficiencies are 
treatable but if left untreated they can lead to abnormal bone metabolism, fractures, neurological 
dysfunction, and anemia.11  Deficiency surveillance is strongly encouraged among these patients 
and should be a top priority for providers who engage in treating this population.          
Discussion: 
         The primary purpose of this study was to examine how intensive medical management 
compares to bariatric surgery in treating diabetes. The author paid special attention to glycemic 
control and comorbid disease risk factors when comparing the two treatment options. This study 
also examines general safety and common adverse side effects seen from bariatric surgery.  
Remission: 
         This review article has identified that bariatric surgery is superior to medical therapy in 
causing remission of diabetes, as evidenced by multiple clinical control trials.7,13-15 Remission of 
diabetes without taking any antidiabetic medications occurred in as little as 6 months for patients 
who were treated with RYGB, ABG, and SG while no patients saw remission in the medical 
therapy group during this short time frame.7 These results remained consistent in studies who 
followed patients for one13, two15, and three years14. 
 Two observations found upon literature review are worth noting. First, patients who 
obtained bariatric surgery saw a decrease of 5% remission rates at 1 year follow up.13 Having 
more strict HbA1c levels as part of remission criteria at 1 year is possibly the reason for this 
difference. 
Secondly, remission rates seen at three years in a RYGB group of 42%14 are markedly 
lower than 75%15 recorded by Mingrone et al., at two year follow up. Though these numbers are 
significantly greater than the medical therapy group, these results bring into question the duration 
in which bariatric surgery shows superiority.  This discrepancy may be explained by the duration 
in which patients in each study were diagnosed with diabetes. The patients in the 3 year follow 
up study recorded an average diagnosis of 10.6 years14 while those who were examined at 2 
years only had an average of 5 years.15 In addition, these results could be tied to patients 
reverting back into old eating habits and discontinuing recommended treatment plans. To this 
affect Dr. McRae commented, “Bariatric surgery is not a magic fix. It does not change people s 
desires to make lifestyle changes and cannot replace healthy habits. Depending on the study, 
approximately 30-63% of patients who undergo a Roux-en-Y procedure will have their type 2 
diabetes go into remission within 1-5 years. Among these patients who experience diabetes 
remission, 35-50% will eventually experience recurrence of the disease. Much of the patient s 
ability to retain the remission status is secondary to their ability to eat healthy, maintain a high 
level of activity and keep the weight off.   
Hemoglobin A1c control 
         In addition to an increase of diabetes remission rates bariatric surgery also shows superior 
control of HbA1c values when compared to medical therapy alone. Multiple studies provide data 
showing that bariatric surgery modalities decrease HbA1c values 6.7.12-19 at greater rates than 
medical therapy. Though the percentages of patients who reached HbA1c values of <6% 
decreased over time in the surgical groups they were still found to be superior to the medical 
therapy groups at 116, 317, and 518 years. The decrease in the percentage of patients with HbA1c 
levels <6% overtime may suggest that at some point there is no superior effect seen with bariatric 
surgery when compared to medical management.   
To that effect, Simonson et al. examined 2 groups of patients, one group who received a 
RYGB and one group who were treated with intensive medical management.14 This study 
examined outcomes at 3 years and found that there was no significant difference in obtaining a 
HbA1c <6% or <7% between the two groups.14 This result is in stark contrast to the patients who 
Schauer (2014)17 examined with the same time frame and surgical modality. 
  Upon evaluation of these two studies there is one major difference among them that could 
contribute to the cause of the subsequent outcomes. The treatments found in patients who were 
among the medical therapy groups were quite different. Simonson et al., treated patients with 
weekly supervised exercise and didactic sessions for the first 3 month of the trial.14 In addition 
these patients underwent weekly medication adjustments as needed, were given a hypocaloric 
diet 1500-1800 kcal/day, and instructed to exercise 300 minutes per week.14 In contrast, Schauer 
(2014) treated patients in the medical therapy group strictly by education of the ADA guidelines. 
This group was educated with lifestyle counseling, weight management (weight watchers 
program), frequent home glucose monitoring, and the use of medication as needed.17 These 
patients also had a follow up every 3 months with a diabetes specialist at the Cleveland clinic.17 
The different management techniques found in these studies are specifically, observed exercise 
of patients and hypocaloric diets. These changes could be a significant cause for the 
improvement of HbA1c values in the non-surgical group which most likely contributed to the 
lack of observing any significant difference in bariatric surgery and medical therapy in the 
Simonson et al., study. 
Antidiabetic Medication Use 
         An important factor to consider when determining superior treatment options for patients 
with type 2 diabetes is the amount or number of medications being used to control this disease. It 
was observed within a number of studies in this review that patients who received bariatric 
surgery needed fewer antidiabetic medications to control glycemic levels when compared to 
medical therapy alone.6,12-14,16,18,19 Ikramuddin et al., examined patients who underwent RYGB or 
medical therapy and found that after 1 year follow up patients in the surgical group were taking 
on average 3 fewer medications to control their diabetes.6 Schauer (2012) et al.,  followed 
patients for 1 year and found that patients in the medical therapy group actually had an increased 
average number of medication being used for hyperglycemia while those who received RYGB or 
SG showed significant decreased (P<0.001).16 Similar results were noted among RYGB patients 
at 3 year follow up which showed that bariatric patients were still taking on average 1.4 less 
medications for glycemic control while the medical therapy group in this study had increased by 
an average of 0.7 medications.14 The mechanism by which bariatric surgery improves glycemic 
control has yet to be discovered but studies have provided correlations between bariatric surgery 
and increased beta cell function, incretin release, and insulin sensitivity 7,12. These correlations 
most likely explain why bariatric surgery patients see a decrease in medication use when 
compared to medical therapy alone. 
It was also observed that there was a significant decrease in the percentage of patients 
who needed insulin to control their diabetes following bariatric surgery when compared to 
medical therapy.12,13,16,19 Schauer (2012) et al., observed that 38% of patients treated with 
medical therapy alone still required use of insulin at 1 year follow up while only 4% and 8% 
needed it in the RYGB and SG groups respectively.16 Cummings et al., found similar results 
observing that 60% of patients in the RYGB group at baseline needed insulin which fell to 27% 
at 1 year follow up. While the medical therapy group saw a decrease from 47% at baseline to 
41% at one year.13 Schauer (2017) followed patients for 5 years and found that only 11% of 
patients in the RYGB and SG group need insulin therapy while 39% required its assistance for 
glycemic control in the medical therapy group.18 These studies provide data which suggests that 
bariatric surgery is superior to medical therapy alone in reducing the percentage of patients using 
insulin. 
 Three points felt important to evaluate during this review. First, the discrepancy between 
the Schauer (2012) study16 and Cumming s et al13., findings which examined RYGB patients at 1 
year and found drastically different percentages of patients still requiring insulin at 4%16 and 
27%13. The differences between these individual studies are vast and possible reasons for the 
observed differences are endless; however, the most notable difference was their percentages of 
patients requiring insulin at baseline in their RYGB group. Schauer (2012) recorded only 46% of 
their RYGB group needed insulin at baseline while 60% of those in the Cumming et al., study 
needed insulin.13,16 In addition, the number of participants were 1513 and 5016 which could also 
contribute to the differences observed, suggesting that the higher the number of participants 
within the study will likely increase the chances of observing more patients not requiring insulin 
for glycemic control. 
Second, a possible reason why at 5 year follow up the same patients observed in Schauer 
(2012)16 had increased their insulin use to 11%18 instead of 4% and 8% seen at 1 year. Diabetes 
is a progressive disease if not properly controlled and will return if proper diet, exercise, and 
other lifestyles changes are not made. Glycemic control is difficult and sustained results largely 
depend on one s ability to make and keep lifestyle changes. Regarding this topic, Dr. McRae 
states “Success with diabetes care is almost exclusively based on patient s motivation to change. 
There is still nothing that can replace the incredible benefits of a healthy lifestyle which not only 
improves morbidity and mortality but has the potential to completely push diabetes type 2 into 
remission.  Patients within the surgical groups may become complacent and fail to remain active 
in combating their diabetes through lifestyle changes. This change may eventually lead them 
back to medications and other treatment options to help control their glycemic levels.  
Third, RYGB seemed to have a slight advantage over SG in decreasing insulin use and 
the total percentage of patients requiring medication. One study showed that 66% percent of 
patients who received RYGB were able to achieve glycemic control while taking no antidiabetic 
medications compared to only 38% seen in SG.12 In addition, another study noted that after 1 
year follow up 8% of patients who received SG needed insulin for glycemic control compared to 
4% who received RYGB .16 The difference noted within these two surgical groups could be 
related to the changes in weight loss following these two different surgical modalities. In both 
studies the RYGB group lost more weight than the SG group did. Other studies7,12 have provided 
evidence that a decrease in weight is related to improved insulin sensitivity. Therefore, the 
reason for decreased insulin use and a greater percentage of patients off antidiabetic medications 
most likely could be attributed to the changes in weight observed in the RYGB compared to the 
SG groups. 
Changes in insulin sensitivity/Pancreatic Beta cell function/Incretins  
         The reason behind increased rates of remission, better HbA1c control, and decreased 
hyperglycemic medication use lies in the metabolic change bariatric surgery creates in diabetic 
patients. Following bariatric surgery through an unknown mechanism patients observe improved 
beta cell function, insulin sensitivity, and increased incretin release significantly more than those 
who were treated with medical therapy alone.7,12  
         In addition to incretins secretion and improved insulin sensitivity, RYGB patients 
observed a 5.8-fold increase in median beta cell functions when compared to the medical therapy 
group.12 However there was no significant change noted in the SG group as opposed to the 
medical therapy group in this study.12 Through a sub cohort study changes in beta cell function 
were attributed to decreased truncal fat and body weight.12 However, there were no significant 
changes in weight or truncal fat noted between the surgical modalities.12 Therefore, the 
difference in these surgical groups effect on beta cells must be explained through other 
mechanisms which likely fall into complex nutrient absorption changes. 
         Overall improved beta cell function will secrete more insulin thus causing an increase in 
incretins levels and improved insulin sensitivity. The changes manifest in cellular proteins 
brought on by a decrease in fat surrounding organs will also improve insulin sensitivity. All of 
these changes seen in bariatric patients lead to improved glycemic control, decreased medication 
use, and higher rates of remission when compared to medical therapy alone. 
Comorbid Risk Factors 
         This study concludes with previous research that bariatric surgery is superior to medical 
management alone in the reduction of weight and related changes to BMI.6,7,12-19 BPD proved to 
be the surgical modality which offered patients the greatest decrease in body weight and BMI.15 
This result can probably be attributed to the nature of this surgery which only leaves a very short 
window to allow absorption of nutrients whereas other surgical modalities involve less extreme 
measures or allow greater areas of bowel to be included for nutrient absorption. Though proven 
to have an increased weight loss BPD also is related to increased number of associated side 
effects such as dumping syndrome and malabsorptive defiencies.11,24 Therefore patients and 
providers should consider the benefits and risks when weighing this treatment option. 
         Previous studies have concluded that blood pressure was significantly decreased in 
bariatric surgery when compared to medical management alone.6,13 However, these results were 
not conclusive with 3 studies found in this review showing that there was not significant 
difference among these two groups. 7,18,19 All of these studies included patients who underwent 
RYGB but different follow up times existed. The earliest study which examined blood pressure 
changes had patients follow up at 6 months.7 This study recorded no significant changes between 
the surgical and medical therapy groups.7 Upon further review of this article it was noted that 
this finding could be a potential weakness. The patients who were included had normotensive 
blood pressures at baseline which most likely led to this insignificant result.7 Additionally, this 
study had a relatively short time frame for follow up at six months when previous studies who 
made positive claims examined patients at 1 year. 
Three studies examined RYGB patients at 1 year for changes in blood pressures.6,13,19 
Serrot et al., in a retrospective review concluded that there was no significant change in BP in the 
surgical group compared to the medical therapy alone.19 In contrast, one additional article 
reported a 28% increase in the percentage of patients who achieved a SBP <130 which was 
significantly more than the non-surgical group.6 Also, one other article found a significant 
decrease in SBP in the RYGB group, which decreased from 129 to 110mmHg on average with 
no significant change in the non-surgical group13.  The major difference among these studies is 
population size. Two studies which report a significant change had a total of 72 patients,6, 13 
while only 17 patients19 were recorded in the article which disagreed.  An increase in population 
size could possibly explain the difference found in these articles. In addition to an increase in 
population size, Ikramuddin et al. studied patients in multiple centers and international locations 
which attributed to the strength of this study s findings.6 In contrast, the Serrot et al. study, which 
had a limited number of patients, also completed the whole trial at the University of Minnesota 
which could have led to selection bias that swayed this studies results.19 
Lastly one study examined blood pressures at 5 years and found no significant difference 
between the surgical and medical therapy groups.18 Therefore, even if a change in blood pressure 
is significantly more in patients who obtain bariatric surgery it is difficult to determine the time 
frame at which these results become null when compared to medical therapy alone. 
 Articles within this review do not offer data or show significant reasons why blood 
pressure changes exist from bariatric surgery though it can be assumed it is due to diet changes 
and a decrease in weight. However, providers and patients should be aware that this review 
shows inconclusive evidence of significant blood pressure changes at 1 year when examining 
bariatric surgery patients as opposed to medical therapy alone. This review agrees that a decrease 
in blood pressures following bariatric surgery occurs, however, these changes are not 
consistently found to be superior to medical therapy alone. 
Lastly, multiple studies were interested in lipid changes found in bariatric surgery and 
how they compared to medical therapy alone. Studies examined results at 6 months7, 1 year,6,13,19 
2 years,12,15 3 years,14,17 and 5 years18. Studies which occurred between 6 months and 2 years 
showed fairly consistent results revealing no significant changes in LDLs, triglycerides, and total 
cholesterol between the two treatment groups.6,7,12,13,19 Only two studies provided data which 
showed significant improvement in high density lipoproteins within the first two years following 
treatment.13,15 This change in HDL could possibly be explained in one study due to it including 
BPD as a surgical modality15 whereas the other studies only used RYGB,6,11,19 SG,7,12 and ABG7. 
BPD is known to cause an increased weight loss when compared to other bariatric surgery 
modalities. As weight loss is associated with increased HDL levels this could explain the 
observed significance. In addition to an increased weight loss Cumming et al., studied patients 
with a BMI less than 3513 while those studies which did not find significant changes in HDL 
levels among the surgical group compared to medical therapy included patients with BMI 
averages above 35.6,7,12,19 Having a lower BMI at baseline suggests a possible healthier 
population more apt to see increases in HDL levels from bariatric surgery then simply medical 
therapy alone. 
In studies which examined patients at 314,17 and 5 years18 results showed decreased levels 
of  LDL14, total cholesterol14, triglyceries14,17,18, and a significant increases in HDL.14,17,18 These 
levels were found to be superior in patients who had undergone bariatric surgery when compared 
to those receiving medical therapy alone.14,17,18 Elevated LDL, TC, and TG levels are associated 
with significant complications in diabetic patients and can lead to life threatening outcomes. 
Therefore, medical providers monitor these levels closely and follow individualized algorithms 
to help decrease chances of significant sequelae. This review was able to observe that bariatric 
surgery begins to show superiority at 3 to 5 years when compared to medical therapy. The reason 
significant changes in lipid values were not observed until 3-5 years remains a mystery and 
would not correlate to changes in metabolism or weight loss as these are significantly affected in 
as early as 6 months.7 Further studies should be called upon to examine the reasoning behind 
these findings.   
Safety and Side Effects of Bariatric Surgery 
         Due to the nature of the surgeries and associated side effects, which have long been 
discussed in the medical community, some patients neglect to consider bariatric surgery as a 
modality to help control their diabetes. One review study examined 15,275 patients who 
underwent AGB, RYGB, and SG. After 30 day follow up, when most severe complication have 
occurred, only 1.5% of patients experience potentially life threatening complication.20 Higher 
rates of complications were observed in the RYGB group compared to SG and ABG groups.20 In 
addition to higher rates of severe complications like venous thromboembolism, cardiac, renal, 
and respiratory failure the RYGB group observed higher death rates.20 This comes as no surprise 
due to the invasive nature of RYGB surgery as compared to SG and ABG. Patients in this study 
had significant risk factors for complications in surgery like an averaged BMI of 46 which put 
them into the morbidly obese category.20 Even with an increased risk, the death toll following  
RYGB in this study was 0.14%, which equates to just over a tenth of a percent chance of dying 
from this procedure.20 An additional review article examining 4610 patients found that bariatric 
surgery carried a 4.1% risk of severe complications however this number is probably inflated due 
to the fact that this study included operative reinterventions as severe complications.21 It was still 
determined that the overall mortality rate among bariatric surgery patients was 0.3%.21 
Interestingly, this study found that extreme BMI values, an inability to walk 200 feet, and history 
of thromboembolism, or sleep apnea correlated with increased complication rates.21 Though 
these studies only identify complications up to 30 days they observed a large population of 
patients and concurred with findings made by previous research that that bariatric surgery is 
relatively safe. When asked about the safety of bariatric surgery Dr. McRae stated “It is 
generally considered a very safe procedure. Although Roux-en-Y surgeries do show more 
patient s that achieve remission of their diabetes, there are more risks involved with the 
procedure compared with the Gastric Sleeve.  Only one study could be identified which 
examined the safety of bariatric surgery in diabetic patients.23 Following patients for 1 year it 
was noted that diabetic patients had a slight increase in minor complications.23 No significant 
difference in severe complications were noted when compared to those without diabetes.23 
Therefore, patients and providers alike may conclude that bariatric surgery is safe not only in the 
general populations but also in patients with diabetes.   
         When examining the long term benefits versus risks following bariatric surgery, one 
study examined patients for an average of 7.1 years following surgery, causes of mortality were 
observed.22 This study noted a significant decrease in mortality rates caused by coronary artery 
disease, diabetes, and cancer in those who had a RYGB. Reduction in coronary artery disease 
and diabetes death can be correlated with a decrease in lipid values and better glycemic control 
following bariatric surgery. This study noted that the decrease in cancer related death is due to a 
decrease in obese patients.22 Previous research has shown considerable evidence that an 
increased risk of cancer is associated with obesity.22 Another possible cause which contributes to 
less cancer related deaths following bariatric surgery is that cancer screening exams may 
improve with weight loss.22 This study, though not solely examining patients with type two 
diabetes, provides patients with the knowledge of long term benefits of bariatric surgery that may 
aid them in making their decision whether or not to pursue surgery as a possible treatment 
option. 
         Lastly, this study, like others,11,24 concludes that bariatric surgery possesses potential 
risks of nutritional deficiencies, anemia, dumping syndrome, abnormal bone metabolism and 
potential neurological symptoms. These risk factors are treatable and should be monitored by the 
providers who take care of these surgical patients. Bariatric surgery modalities which bypass the 
stomach or portions of the small bowel like RYGB and BPD are more commonly associated with 
complications.11,24 All in all, bariatric surgery is safe and through proper surveillance with follow 
up visits patients can avoid or at least treat these common nutritional complications. 
         Limitations within each article were plentiful. The sample size was extremely small for 
several studies which examined the comparison between bariatric surgery and medical therapy in 
treating diabetes. Many studies had less than 100 participants overall, which makes it difficult to 
draw conclusions that can be applied to broad populations. In addition to small populations, it 
was noted that most studies in this review had a significantly higher proportion of women over 
men. This could potentially sway results or at least detract from the number of conclusions that 
can be applied to male patients with diabetes. Other limitations include many of the studies 
differing widely in the duration of diabetes among the examined patients which could have 
altered rates of remission and other levels of glycemic control. Variations in medical therapy 
existed among studies which could have led to significant findings in some studies between the 
two treatment groups but not in others. Due to the individualized nature of diabetes treatment and 
the significant variations in medications used, an exact comparison among the medical therapy 
and surgical groups between studies would be impossible. This makes observed results 
extremely generalized and less specific. Some studies examined minority populations, which 
creates difficulty when applying results to the general population. Certain cofounding factors 
were unable to be eliminated. Many of the patients with diabetes are also diagnosed with other 
diseases. These studies did not examine other diagnoses in addition to diabetes on an individual 
basis, which could have related to reported changes. Lastly, and probably the most important 
limitation observed is the limited duration of follow up found among the studies. An extremely 
limited number of studies exist which reviewed outcomes in diabetic patients following bariatric 
surgery beyond 2 years. Which leaves practitioners and patients questioning on the duration of 
time that surgery may be effective. 
Conclusion: 
         Current literature demonstrates that bariatric surgery is an effective treatment option for 
diabetes. Especially, for patients who have been diagnosed with obesity, struggle with glycemic 
control, and are unable to make significant lifestyle changes. Bariatric surgery supplies patients 
with higher rates of remission from diabetes when compared to medical therapy alone. In 
addition, bariatric surgery proved superior in controlling HbA1C levels, decreasing weight, and 
lowering the amount/number of medications used by patients for glycemic control. Interestingly, 
patients who have undergone bariatric surgery observe improved beta cell function, insulin 
sensitivity, and increased incretin release. Contrary to previous research hypotheses blood 
pressure changes did not prove to be significantly better in the surgical groups when compared to 
medical therapy. Another noteworthy conclusion was made evident by the patients  lipid 
profiles, which were not consistently superior in the surgical group until 3-5 years following the 
operation. Specifically, patients observed a decrease in total cholesterol, low density 
lipoproteins, and triglycerides, while high density lipoproteins were found to significantly 
increase. Patients who obtain bariatric surgery are at risk of nutritional deficiencies, anemia, 
dumping syndrome, abnormal bone metabolism and potential neurological symptoms. In 
addition, patients who are diagnosed with diabetes may expect to see higher rates of minor 
complications following bariatric surgery compared to those who do not have diabetes. However, 
patients with diabetes do not experience higher rates of severe complications. In general, 
bariatric surgery is a very safe procedure with exceptionally low rates of significant 
complications or death. Long term benefits following surgery include a decreased death rate 
from coronary artery disease, diabetes, and cancer.  When Dr. McRae was asked about his 
conclusions regarding this topic he stated: “Bariatric surgery is an excellent option to jumpstart 
the weight loss process. Even with weight regain over the years and reoccurrence of diabetes, 
patients tend to regain weight slower, require less medication, and their diabetes process does 
better in the long run. Bariatric surgery is by far most successful when combined with lifestyle 
interventions and appears to also be a good option for those who aren't able or willing to make 
intensive lifestyle changes.  Patients and providers alike should consider and review bariatric 
surgery as a possible treatment option for uncontrolled diabetes. Patients must weigh the risks 
against long term benefits while making their decision in pursuing surgical options as treatment. 
         Future research involving a significant number of participants diagnosed with diabetes 
who qualify for bariatric surgery is needed. An ideal prospective study would include at least 
1000 patients from different ethnic backgrounds with an equal number of men and women. 
Making sure to avoid significant baseline difference, cohorts should be matched by: weight/BMI, 
duration of diabetes diagnosis, A1C levels, insulin use/ number of medications, blood pressures, 
lipid profiles, race, age, and sex assigned at birth. Participants in the medical therapy group 
should be treated to ADA standards, preferably observed exercises, premade provided meals or 
structured standardized nutrition plan, and strict follow-up on medication use including quarterly 
follow up appointments to manage medications and examine lab values with physicians not 
involved in the study. The surgical groups should undergo RYGB, BPD, GS, ABG in equal 
amounts, all, receiving the same technique for the respected surgeries. Factors to be observed 
should include: remission rate according to ADA standards, HbA1c levels, fasting blood glucose 
values, number of medications being used to control diabetes, weight, lipid profiles (LDL, HDL, 
TC, TRI), blood pressure, side effects which required medical attention and deaths. The optimal 
duration would be for at least 10 years to acquire more long-term statistics. This study design 
should be feasible as other studies in the past have used similar approaches but did not follow up 
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Appendix A (Prompt from Dr. McRae Interview) 
1)      Is it difficult to manage patients with diabetes solely on medication and lifestyle 
changes?  
  
It depends. Success with diabetes care is almost exclusively based on patient s motivation to 
change. Recently, several diabetes medications have been developed which contribute to weight 
loss, cardiovascular and renal protection. All of these are excellent for improvement in outcomes 
in morbidity and mortality. All of this aside, there is still nothing that can replace the incredible 
benefits of a healthy lifestyle which not only improves morbidity and mortality but has the 
potential to completely push diabetes type 2 into remission.    
  
2)      If it is yes to the previous question, how does bariatric surgery help? Who do you 
suggest it for? 
  
Habits are hard to break. Not only this, but most of our current environments make it very 
difficult to lose weight and make drastic lifestyle changes. Patients who I have seen benefit the 
most from surgery are those who want to exercise but are unable to due to their body habitus. 
Bariatric surgery has also provided an additional option for those who have struggled making 
significant lifestyle change and seek to wean off many of their medications, lose weight, improve 
labs, etc. The ADA (American Diabetes Association) recommends bariatric surgery as an option 
for type 2 diabetes with BMI >40 (Asia American populations have different BMI cutoffs), BMI 
30-40 w/ comorbidities and difficulty achieving weight loss. 
  
3)      In your experience has bariatric surgeries changed peoples A1C, Fasting blood 
glucose, or Random Glucose labs? Do you see a decrease in medication use or even a 
remission in diabetes altogether? Do you see changes in lipids profiles, weight loss, and 
other comorbidities? 
  
Bariatric surgery is not a magic fix. It does not change people s desires to make lifestyle changes 
and cannot replace healthy habits. Depending on the study, approximately 30-63% of patients 
who undergo a Roux-en-Y procedure will have their type 2 diabetes go into remission within 1-5 
years. Among these patients who experience diabetes remission, 35-50% will eventually 
experience recurrence of the disease. Much of the patient s ability to retain the remission status is 
secondary to their ability to eat healthy, maintain a high level of activity and keep the weight off. 
With bariatric surgery, we often see a significant improvement in blood pressures, lipid profiles, 
blood sugars, decrease in medication requirement, etc. There is still no randomized control trial 
that I am aware of that shows an improvement in type 2 diabetes mortality following bariatric 
surgery.  
  
4)      Is bariatric surgery safe? What are the major risk factors or adverse outcomes for 
these patients moving forward? What is the long term outcome >5 years? Do these 
patients have remission of diabetes or overtime develop the same significant issues that 
once were eliminated?  
  
It is generally considered a very safe procedure. Although Roux-en-Y surgeries do show more 
patient s that achieve remission of their diabetes, there are more risks involved with the 
procedure compared with the Gastric Sleeve. The bypass surgery is a much longer procedure, 
there are more vitamin deficiencies, dumping syndrome, hypoglycemia, etc.  
  
5)      Any thoughts on how bariatric surgery works in treating type 2 diabetes? 
  
The complete mechanism behind how bariatric surgery improves outcomes in type 2 diabetes is 
unclear. Many patients will begin having significant drops in their blood sugar and insulin 
requirements immediately following surgery before any weight loss occurs. The improvement in 
lipid profiles, blood pressures and blood sugars secondary to weight loss can be explained by the 
improvement in insulin resistance. When fat is removed from tissues such as the liver, muscles, 
pancreas, etc. then the insulin receptor begins working much better. This allows the endogenous 
insulin produced by the pancreas to start working much better and subsequently improves blood 
sugars, lipid profile and blood pressures.  
  
6) Any conclusions you wish to make on this topic? 
  
Bariatric surgery is an excellent option to jumpstart the weight loss process. Even with weight 
regain over the years and recurrence of diabetes, patients tend to regain weight slower, require 
less medication and their diabetes process does better in the long run. Bariatric surgery is by far 
most successful when combined with lifestyle interventions and appears to also be a good option 
for those who aren t able or willing to make intensive lifestyle changes.           

